ABSTRACT
The deleted in colorectal cancer (DCC) gene encodes a neural cell adhesion family molecule that was originally identified as a candidate tumor suppressor target of 18q allelic loss in colorectal cancer. However, the importance of the DCC protein has been most clearly demonstrated in neural development. Mutational and subsequent biochemical studies in C. elegans, Drosophila and vertebrates have shown that DCC functions in the guided migration of cells and cell processes in response to stimuli from netrins, a family of secreted laminin-like proteins. It appears that DCC may act in this signal transduction pathway as a netrin receptor or a component of the receptor complex, though a definitive receptor:ligand relationship has not yet been demonstrated. It is also clear that DCC can affect migrations in a netrin-independent manner, implying the existence of other DCC ligands. Though the loss of DCC expression appears to be a later event in several malignancies and is associated with disease dissemination, it has not been adequately demonstrated that DCC is the tumor suppressor gene targeted by 18q allelic loss. However, DCC expression does have potential clinical utility as it stratifies an important group of colorectal cancer patients into good and poor prognosis subgroups.
INTRODUCTION
The DCC (deleted in colorectal cancer) gene was originally identified through studies of the progressive stages of ________________________________________________ Received 8/25/97 Accepted 9/5/97 Michael A. Reale The common region of loss at 18q21.3 was found to contain the extraordinarily large DCC gene (1.35 megabases, 29 exons) (3, 4). The sequence of the DCC cDNA predicts a 1447 amino acid transmembrane protein with extracellular immunoglobulin and fibronectin type III domains typical of the neural cell adhesion molecule (NCAM) family of proteins (4-6). DCC and neogenin, a protein whose expression is dynamically regulated in chicken neural development, define an NCAM subfamily on the basis of their unique constellation of extracellular domain motifs (six immunoglobulin and four fibronectin type III domains) and cytoplasmic domain (7). Their approximately 325 amino acid cytoplasmic domains do not share similarity with any other proteins in the data base (Figure 1 ). Several DCC homologs have been isolated and cloned from both invertebrates and vertebrates (8-12). DCC has been highly conserved in vertebrate evolution as the sequence predicted by the human cDNA shares co-linearity and greater than 75% overall identity at the amino acid level to the cDNA for a Xenopus laevis homologue of DCC (12) ( Figure  1 ).
The expression pattern of the DCC gene in adult tissues is informative as levels of expression in the central and peripheral nervous system far exceed those of non-neural tissues (5, 6, 11, 12). Alternative splicing involving both the extracellular and cytoplasmic domains of the DCC protein has been described, though the functional significance of these splicing events is not yet understood (6, 11, 13). 
DCC AND DEVELOPMENT
Studies in the developing chicken have implicated DCC in the epithelial-mesenchymal interactions of feather bud formation and have begun to characterize its expression in developing epithelia (14). However, the majority of studies have focused on DCC in neural differentiation and development. DCC antisense and overexpression studies in the rat pheochromocytoma (PC12) model system have suggested a role for DCC in the induction of neuronal differentiation (15, 16). Work in the mouse (11) and Xenopus laevis (12) have demonstrated that DCC expression is highest in the neural tube and developing forebrain, midbrain and hindbrain, and this expression is developmentally regulated. Moreover, DCC was expressed as a consequence of neural induction in the Xenopus system. These studies suggested an important functional role for DCC in developing neural tissue, a role that would be characterized in the studies described below.
DCC guides axonal migrations
The guided migration of axons to connect with a specific target cell is a fundamental process in developmental neurobiology. It has become increasingly clear that this process involves both attractive and repulsive environmental cues that act via signal transduction mechanisms to assist the growth cone in finding its proper pathway (17, 18). The netrins are one such family of guidance molecules. Netrins were originally identified as the activity in rat floor plate cells that can promote the outgrowth of commissural axons from rat dorsal spinal cord explants (19, 20) . These proteins constitute a family of highly phylogenetically conserved molecules related to the extracellular matrix protein, laminin (20, 21).
The netrin response pathway has begun to be clarified with mutational studies primarily in C. Elegans (8, 22) . These studies have demonstrated that the products of the unc-5, unc-6 and unc-40 ("uncoordinated") genes are required for proper dorsoventral migrations of commissural axons (Figure 2) . unc-40 is now known to be a C. elegans homolog of DCC (8), while unc-6 is a netrin homolog (20, 23). unc-5 is a transmembrane protein characterized by extracellular immunoglobulin and thrombospondin-1 domains and a cytoplasmic domain that is similar to the ZO-1 tight junction protein (24, 25).
Netrin/unc-6 function requires either unc-5 or DCC /unc-40, and mutations in netrin/unc-6 affect both ventral and dorsal migrations of commissural axons. unc-5 mutations affect only dorsal axonal migrations, and there has been no demonstration as yet that unc-5 can function independently of netrin/unc-6. DCC/unc-40 acts cell autonomously to predominantly affect ventral migrations, though it is also required along with unc-5 for dorsal migrations (Figure 2 ). It is noteworthy that the phenotype of DCC/unc-40 null mutations is less severe than mutations which result in truncated DCC/unc-40 proteins. These nematode studies have been supported by work in Drosophila where the DCC homolog, frazzled, has been shown to be important primarily in ventral axonal migrations (10). Recent studies of netrin-1 (28) and DCC These mutational studies clearly suggest a ligand:receptor relationship for netrins and DCC and/or unc-5, and there is now biochemical evidence in support of this hypothesis. Keino-Masu et al. (9) have shown that netrins bind specifically to DCC expressing cells and that a monoclonal antibody directed to the DCC extracellular domain can abrogate netrin-mediated axonal outgrowth in vitro. Interestingly, this antibody blockade did not affect binding of netrin to the DCC expressing cells. Similar studies have also shown the ability of netrin to bind specifically to unc-5 expressing cells. A simplistic model consistent with these findings is that DCC mediates attractive responses to a netrin gradient, while unc-5 mediates a repulsive response. Refinement of this model awaits further definition of the actual receptor complex(es), since one interpretation of the above data is that DCC and unc-5 are modifiers of the actual receptor (24, 25). Also, this model does not adequately explain the findings that unc-5 repulsive function requires DCC/unc-40 and the more severe phenotypes seen with truncated forms of DCC/unc-40. A heteromeric receptor in which truncated DCC/unc-40 acts in a dominant negative fashion has been hypothesized (26).
DCC guides cell migrations
While DCC has not had any apparent effects on cell proliferation in developmental models, it has been shown to provide pathway guidance for mesodermal and ectodermal cell migrations. Ventral migrations of the mesodermal male linker cell are abnormal in C. elegans DCC/unc-40 mutants, as are migrations of the ectodermal Q neuroblasts and P ectoblasts. The latter two defects are netrin-independent.
The Q neuroblast defect is of particular interest because it has been linked to defects in wingless/wnt signaling in C. elegans (8). The wingless/wnt cell fate determination pathway is mediated by beta-catenin (armadillo), an oncogenic protein that is required for cadherin-mediated cell adhesion in addition to its role in signaling (30). The antagonism of beta-catenin signaling function by an interaction with the APC tumor suppressor protein further emphasizes the role of the developmentally important beta-catenin protein in cancer (31, 32). The significance of the potential relationship between DCC/unc-40 mediated Q neuroblast migration and wingless/wnt signaling remains to be elucidated (8).
In DCC -/-mice the pontine nuclei at the base of the rostral midbrain are absent (29), a defect that is also seen in netrin-1 deficient mice (28). Though it has not yet been rigorously shown that this represents a mismigration, this seems likely as these nuclei arise in a manner similar to that of spinal commissural axons. They must undergo a ventral, circumferential migration of cells from the lateral recess of the IVth ventricle to their final position in the pons (33). Refers to expression in primary tumor unless otherwise noted.
Summary
The DCC protein is of unequivocal importance in development, particularly of neural tissue. It functions in the guided migration of cells and cell processes as a component of the netrin response pathway. It appears that DCC may act in this signal transduction pathway as a netrin receptor or a component of the receptor complex, though a definitive receptor:ligand relationship has not yet been demonstrated. It is also clear that DCC can affect migrations in a netrin-independent manner, implying the existence of other DCC ligands.
DCC AND CANCER

18q Allelic loss and DCC expression studies
Allelic loss involving the long arm of chromosome 18 is a frequent event in a variety of malignancies and is therefore likely the site of a tumor suppressor gene(s). Tumors of diverse tissue origins are affected by these deletions--bladder, breast, colon, endometrium, esophagus, germ cell, neural crest (neuroblastoma), osteosarcoma, ovary, pancreas, prostate and stomach (Table 1 ). The DCC gene is a candidate target for this 18q deletion event on the basis of its location within the minimally lost region (18q21.3), some evidence of mutations within the remaining DCC allele and frequent loss of DCC expression.
In colorectal and esophageal cancer the remaining DCC allele has been shown to be affected by localized somatic mutations in only a subset of cases. Single point mutations have been found in intron 5, intron 13, exon 3 and exon 28 (3, 4, 52), and approximately 10-15% of colorectal cancer cases have expansions in a dinucleotide repeat tract immediately downstream of one of the exons (4). Although the effect of this expansion on DCC expression is unclear, Campuzano et al. (79) have found that a large expansion of a trinucleotide repeat sequence within the first intron of the Friedreich's Ataxia gene accounts for the majority of the germline mutations causing this syndrome and that the mutant alleles fail to express stable transcripts. No familial mutations in DCC that confer a predisposition to tumor formation have yet been described. It is noteworthy that less than 1% of the 1.35 megabase DCC gene has been analyzed for mutations to date. There have also been no significant studies to address the possibility of methylation silencing of the DCC gene, a mechanism now known to achieve tumor suppressor gene inactivation in several cases (80, 81) .
Two other candidate target genes, both members of the MAD-related family of proteins essential in TGF-beta signaling, have been identified in the minimally lost region of 18q21 (70, 82) . The DPC4 /Smad4 gene has been shown to be a target of 18q deletions and localized mutations in pancreatic cancer (70) , and this study showed that DCC was likely not targeted by allelic loss in this malignancy. However, more recent studies have shown that DPC4 /Smad4 mutations can account for, at most, one third of the 70% 18q allelic loss seen in colorectal cancer (83, 84) , and that DPC4 is seldom mutated in a variety of other cancers studied (85) (86) (87) (88) . The second target candidate, JV18-1/MADR2, has been shown to be mutated in 6% of colorectal tumors studied, but was not altered in a large panel of breast carcinomas and sarcomas (82, 89) . It appears that the majority of 18q allelic loss in colon cancer and other malignancies cannot presently be accounted for by alterations in DPC4 /Smad4 and/or JV18-1/MADR2. While most are cured by surgery alone, a significant proportion will die of their disease and there has previously been no effective means of defining this biologically aggressive subset. DCC expression may fill this void and certainly will be an important stratifying variable in future studies of adjuvant chemotherapy in stage II and III patients (90) . DCC expression has also been examined by immunoblot and immunohistochemistry in a large panel of primary neuroblastomas (n=84), a pediatric tumor of neural crest origin (65, unpublished data). Allelic loss involving the DCC locus had previously been shown to be the second most frequent site of allelic loss in this malignancy (66). The DCC protein was absent in 36% of the primary tumors overall, and tumors from patients with advanced stage or disseminated disease were much more frequently DCCnegative. Consistent with this association between the absence of the DCC protein and disease dissemination, metastatic deposits were more frequently DCC-negative [9/11 (82%)] than primary tumors.
Despite the
The study of Reyes-Mugica et al. (60) is particularly noteworthy as it overcame a fundamental problem in all studies that attempt to compare precursor cells with their malignant counterpart --the uncertain cellular origin of most tumors. Though many glioblastomas arise rapidly in a de novo fashion (i.e. without demonstrable precursor lesions), a subset arise from precursor astrocytomas/anaplastic astrocytomas (91) (92) (93) . Moreover, sequential resections are often performed in these patients so that matched pair tumors from the same site in the same patient provide an opportunity to directly assess the molecular basis of tumor progression. These investigators exploited the astrocytoma --> glioblastoma sequence to examine the role of the DCC gene in glioma progression. Their examination of paired astrocytoma-glioblastoma specimens directly demonstrated the loss of DCC expression with glioma progression in approximately 50% of cases. This study provided further evidence that alterations in DCC expression are generally a later event in the malignant process and also linked DCC loss of expression to the development of the highly invasive glioblastoma multiforme.
Experimental approaches
Three studies have directly addressed the question of a tumor suppressor function for the DCC protein. All three studies can be criticized as their endpoint of cell growth may not be the most relevant endpoint for a molecule such as DCC. The developmental studies described above have demonstrated DCC's role in the guidance of cell migrations and failed to show any affect on cell proliferation. Moreover, the reduction in DCC expression in tumors appears to be a later event in the malignant process and is associated with the process of dissemination (44, 45, 52, 60, unpublished data). Correlates of the complex processes important in disease dissemination -attachment, invasion, angiogenesismay be more appropriate endpoints.
Summary
Though DCC was originally implicated as a suppressor of tumor initiation or formation, the present data, particularly the lack of demonstrated mutational inactivation of the remaining allele and the absence of a predisposition to tumor formation in DCC-deficient mice, argue that DCC may not be a tumor suppressor. Further studies of the minimally lost region at 18q21 should be informative in terms of identifying another target gene or elucidating the mechanism of apparent DCC gene inactivation.
The reduction or loss of DCC expression appears to be a later event in several malignancies and is associated with disease dissemination. Taken together with DCC's role in responding to extracellular matrix cues during development, future studies should focus on a possible role for DCC in the metastatic process. DCC expression has potential clinical utility as it can stratify an important subgroup of colorectal cancer patients in terms of survival.
DCC expression should be a stratifying variable in future therapeutic trials in colorectal cancer, and its ability to stratify patient populations should be further addressed in malignancies such as gliomas and neuroblastomas.
PERSPECTIVE
The importance of DCC in the migration of cells and their processes during neural development and cellular differentiation is evident. While reduction/loss of DCC expression appears to be a later event in the malignant process and is associated with disease dissemination, a definitive role for DCC as an inhibitor of the malignant process is less clear. In light of the frequent crosstalk between developmental studies and cancer biology (30, 31, 95), it is intriguing to speculate that the developmental role of DCC in cell/cell process pathfinding indicates a similar role in the analogous process of tumor dissemination.
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